CVS Health Co. (NYSE:CVS) Shares Sold by Glenview Trust co

Glenview Trust co lessened its holdings in shares of CVS Health Co. (NYSE:CVS) by 80.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,785 shares of the pharmacy operator’s stock after selling 126,730 shares during the period. Glenview Trust co’s holdings in CVS Health were worth $1,382,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Frank Rimerman Advisors LLC grew its stake in shares of CVS Health by 63.3% during the fourth quarter. Frank Rimerman Advisors LLC now owns 11,787 shares of the pharmacy operator’s stock worth $529,000 after acquiring an additional 4,571 shares during the last quarter. Intact Investment Management Inc. boosted its stake in CVS Health by 240.8% in the 4th quarter. Intact Investment Management Inc. now owns 274,000 shares of the pharmacy operator’s stock worth $12,300,000 after purchasing an additional 193,600 shares in the last quarter. Aviso Financial Inc. increased its stake in CVS Health by 52.6% during the 4th quarter. Aviso Financial Inc. now owns 14,104 shares of the pharmacy operator’s stock valued at $633,000 after purchasing an additional 4,862 shares in the last quarter. LBP AM SA purchased a new position in shares of CVS Health in the fourth quarter worth $6,541,000. Finally, Madison Investment Advisors LLC acquired a new stake in shares of CVS Health during the fourth quarter worth $6,233,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on CVS. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Evercore ISI upped their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Barclays raised their target price on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Piper Sandler cut their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research report on Monday, November 25th. Finally, Argus set a $77.00 price objective on CVS Health in a report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $69.83.

Insider Buying and Selling

In other CVS Health news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by company insiders.

CVS Health Price Performance

NYSE:CVS opened at $65.63 on Monday. The stock has a 50 day moving average of $58.47 and a two-hundred day moving average of $56.98. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The firm has a market cap of $82.75 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.05%. CVS Health’s dividend payout ratio is presently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.